section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,evidence_source
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,name_en,Male Hypogonadism,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,description,男性睾丸产生睾酮不足或无法产生足够精子的内分泌疾病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,icd_10,E29.1,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,epidemiology.prevalence,40岁以上男性约20%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,epidemiology.incidence_rate,随年龄增长而增加,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,epidemiology.age_distribution,50岁后发病率显著上升,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,epidemiology.risk_factors,年龄; 肥胖; 糖尿病; 代谢综合征; 慢性疾病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_mechanism.primary.description,睾丸本身疾病导致,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_mechanism.primary.causes,Klinefelter综合征; 睾丸创伤; 睾丸炎; 化疗或放疗; 先天性睾丸发育异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_mechanism.primary.hormone_pattern,低睾酮，高LH/FSH,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_mechanism.secondary.description,下丘脑-垂体轴异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_mechanism.secondary.causes,垂体肿瘤; Kallmann综合征; 慢性疾病; 药物（糖皮质激素、阿片类）; 营养不良,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_mechanism.secondary.hormone_pattern,低睾酮，低或正常LH/FSH,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_onset.congenital,先天性，青春期前发病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,classification.by_onset.acquired,获得性，成年后发病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,clinical_manifestations.sexual_symptoms,性欲减退; 勃起功能障碍; 射精量减少; 不育,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,clinical_manifestations.physical_signs,肌肉量减少; 骨密度降低; 体脂增加; 胡须和体毛稀少; 睾丸萎缩,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,clinical_manifestations.psychological_symptoms,抑郁; 易怒; 疲劳; 注意力不集中; 记忆力下降,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,clinical_manifestations.metabolic_effects,胰岛素抵抗; 血脂异常; 骨质疏松; 贫血,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.total_testosterone.normal_range,10.4-34.7 nmol/L (300-1000 ng/dL),American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.total_testosterone.timing,上午8-11时采血,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.total_testosterone.repeat_testing,低值需要重复检测,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.free_testosterone.calculation,基于总睾酮和SHBG计算,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.free_testosterone.direct_measurement,平衡透析法或超离心法,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.gonadotropins.LH,区分原发性和继发性,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.gonadotropins.FSH,评估生精功能,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.other_hormones,催乳素; 甲状腺功能; 皮质醇,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.questionnaires,ADAM问卷; qADAM问卷; AMS评分,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.imaging.scrotal_ultrasound,评估睾丸大小和结构,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,diagnosis.imaging.pituitary_mri,怀疑垂体疾病时,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.indications,明确诊断的性腺功能减退; 有症状且实验室确认; 无禁忌症,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.formulations.intramuscular.testosterone_enanthate,250mg q2-4周,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.formulations.intramuscular.testosterone_undecanoate,1000mg q10-12周,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.formulations.topical.gel,50-100mg/day，每日应用,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.formulations.topical.patch,2-6mg/day,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.formulations.oral.testosterone_undecanoate,120-160mg bid,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.formulations.pellet.subcutaneous,150-450mg q3-6月,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.testosterone_replacement.contraindications,前列腺癌; 乳腺癌; 未治疗的睡眠呼吸暂停; 严重心力衰竭; 红细胞增多症,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.monitoring.efficacy,症状改善; 睾酮水平; 骨密度; 肌肉量,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.monitoring.safety,血细胞计数; 肝功能; 脂质代谢; 前列腺特异抗原(PSA); 前列腺检查,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.monitoring.frequency,治疗前3-6个月每3个月，之后每6-12个月,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,complications.untreated_consequences,骨质疏松和骨折; 心血管疾病风险增加; 代谢综合征; 抑郁和认知功能下降; 不育,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,complications.treatment_related,红细胞增多症; 睡眠呼吸暂停加重; 前列腺增生; 皮肤反应（外用制剂）,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,prognosis.with_treatment,大多数患者症状显著改善,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,prognosis.quality_of_life,性功能和整体健康状况改善,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,prognosis.long_term_outcomes,需要终生治疗和监测,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,prognosis.fertility,部分患者可通过hCG或FSH治疗恢复生育能力,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,name_en,Andropause/Late-onset Hypogonadism,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,description,中老年男性由于睾酮水平逐渐下降引起的综合征候群,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,icd_10,E29.1,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,epidemiology.prevalence,40-79岁男性约6-12%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,epidemiology.age_onset,通常40岁后开始,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,epidemiology.progression,睾酮水平每年下降1-2%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,epidemiology.individual_variation,存在显著个体差异,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,pathophysiology.hormonal_changes.testosterone_decline,总睾酮和游离睾酮逐渐下降,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,pathophysiology.hormonal_changes.shbg_increase,性激素结合球蛋白增加,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,pathophysiology.hormonal_changes.lh_elevation,促黄体激素轻度升高,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,pathophysiology.contributing_factors,睾丸老化; 下丘脑-垂体轴敏感性下降; 慢性疾病; 药物影响; 生活方式因素,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,clinical_manifestations.core_symptoms,性欲减退; 勃起功能减退; 精力下降; 疲劳感,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,clinical_manifestations.physical_changes,肌肉量减少; 腹部脂肪增加; 骨密度下降; 体毛减少,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,clinical_manifestations.psychological_symptoms,情绪低落; 易怒; 焦虑; 记忆力下降; 注意力不集中,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,clinical_manifestations.metabolic_effects,胰岛素敏感性下降; 血脂异常; 血压升高,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.clinical_evaluation.symptom_assessment,使用标准化问卷,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.clinical_evaluation.physical_examination,全面体格检查,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.clinical_evaluation.medical_history,评估合并症和用药史,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.testosterone_measurement.timing,上午采血,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.testosterone_measurement.repeat_testing,异常值需确认,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.testosterone_measurement.cutoff_values,各实验室参考值略有不同,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.laboratory_tests.additional_tests,促性腺激素; 催乳素; 甲状腺功能; 糖化血红蛋白,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,diagnosis.differential_diagnosis,抑郁症; 慢性疲劳综合征; 甲状腺功能减退; 糖尿病并发症,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.conservative_management.lifestyle_modifications,规律运动; 健康饮食; 充足睡眠; 戒烟限酒; 压力管理,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.conservative_management.weight_management,减重可显著改善睾酮水平,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.conservative_management.exercise_program,抗阻训练和有氧运动结合,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.hormone_therapy.indications,症状明显且睾酮水平低于正常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.hormone_therapy.contraindications,与年轻男性相同,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.hormone_therapy.special_considerations,前列腺癌筛查; 心血管风险评估; 睡眠呼吸暂停评估,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,treatment.alternative_treatments,磷酸二酯酶5抑制剂（勃起功能障碍）; 抗抑郁药（情绪症状）; 认知行为治疗,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,monitoring.effectiveness,症状改善评估; 生活质量量表; 性功能评估,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,monitoring.safety_monitoring,前列腺检查; 心血管风险因子; 骨密度检测; 血液学检查,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,prognosis.natural_history,症状可能进行性加重,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,prognosis.treatment_response,多数患者治疗后症状改善,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,prognosis.long_term_management,需要个体化长期管理,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,prognosis.quality_of_life,适当治疗可显著提高生活质量,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,name_en,Male Infertility,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,description,夫妇正常性生活未避孕12个月未能妊娠，男方因素导致的生育能力障碍,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,icd_10,N46,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,epidemiology.prevalence,影响15%的夫妇，男性因素占50%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,epidemiology.regional_variation,中国不育症发病率约10-15%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,epidemiology.trend,近年来发病率有上升趋势,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,epidemiology.age_factor,男性年龄对精子质量有影响,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.hormonal_factors.percentage,1-2%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.hormonal_factors.causes,下丘脑-垂体-性腺轴异常; 性腺功能减退; 高催乳素血症; 甲状腺功能异常; 肾上腺疾病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.genetic_factors.percentage,10-15%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.genetic_factors.conditions,Klinefelter综合征; Y染色体微缺失; 囊性纤维化基因突变; Kallmann综合征,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.anatomical_abnormalities.percentage,10-20%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.anatomical_abnormalities.types,精索静脉曲张; 隐睾; 输精管缺如; 射精管阻塞; 尿道下裂,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.infections.percentage,6-10%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.infections.pathogens,腮腺炎病毒; 衣原体; 淋病奈瑟菌; 结核杆菌; 大肠杆菌,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.environmental_occupational,高温环境; 电磁辐射; 化学物质接触; 重金属暴露; 农药接触,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.lifestyle_factors,吸烟; 过量饮酒; 肥胖; 营养不良; 过度运动; 药物滥用,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,etiology.idiopathic,原因不明占25-30%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_semen_analysis.oligospermia,精子浓度<15×10^6/ml,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_semen_analysis.asthenospermia,前向运动精子<32%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_semen_analysis.teratospermia,正常形态精子<4%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_semen_analysis.azoospermia,精液中无精子,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_semen_analysis.oligoasthenoteratospermia,三项指标均异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_mechanism.pretesticular,下丘脑-垂体异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_mechanism.testicular,睾丸本身疾病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,classification.by_mechanism.posttesticular,输精管道异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.medical_history,生育史; 性功能史; 既往疾病史; 手术史; 用药史; 职业环境暴露史,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.physical_examination.general,身高体重，第二性征,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.physical_examination.genital,阴茎检查; 睾丸大小和质地; 附睾触诊; 精索静脉曲张检查; 输精管触诊,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.physical_examination.special_tests,直肠指检（怀疑射精管阻塞）,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.laboratory_tests.semen_analysis.parameters,精液量; 精子浓度; 总精子数; 精子活动力; 精子形态,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.laboratory_tests.semen_analysis.requirements,禁欲2-7天，2次检查间隔1-3周,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.laboratory_tests.hormonal_evaluation.indications,精子浓度<10×10^6/ml; 性功能异常; 临床怀疑内分泌异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.laboratory_tests.hormonal_evaluation.tests,FSH; LH; 睾酮; 催乳素; 甲状腺功能,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.laboratory_tests.genetic_testing.indications,无精症; 严重少精症; 家族史; 反复流产史,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.laboratory_tests.genetic_testing.tests,染色体核型; Y染色体微缺失; 囊性纤维化基因,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.imaging_studies.scrotal_ultrasound,精索静脉曲张; 睾丸大小和回声; 附睾异常,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,clinical_assessment.imaging_studies.transrectal_ultrasound,射精管阻塞评估,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.hormonal_therapy.hypogonadotropic_hypogonadism.hcg_therapy,2000-5000IU每周2-3次,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.hormonal_therapy.hypogonadotropic_hypogonadism.fsh_therapy,75-150IU每周3次,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.hormonal_therapy.hypogonadotropic_hypogonadism.duration,通常需要3-6个月,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.hormonal_therapy.hyperprolactinemia,多巴胺激动剂,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.hormonal_therapy.thyroid_disorders,甲状腺激素替代,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.empirical_therapy.antioxidants,维生素E; 维生素C; 辅酶Q10; 左卡尼汀,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.empirical_therapy.duration,至少3个月,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.medical_management.empirical_therapy.evidence,有限的循证医学证据,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.surgical_treatment.varicocelectomy.indications,可触及的精索静脉曲张; 精液质量异常; 睾丸萎缩,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.surgical_treatment.varicocelectomy.techniques,显微镜下手术; 腹腔镜手术; 经皮栓塞,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.surgical_treatment.varicocelectomy.success_rate,60-80%精液质量改善,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.surgical_treatment.obstructive_procedures,输精管-附睾吻合术; 输精管-输精管吻合术; 射精管切开术,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.assisted_reproductive_technology.intrauterine_insemination.indications,轻中度精液异常; 性功能障碍; 免疫性不育,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.assisted_reproductive_technology.intrauterine_insemination.success_rate,10-20%每周期,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.assisted_reproductive_technology.ivf_icsi.indications,严重精液异常; IUI失败; 其他ART指征,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,treatment.assisted_reproductive_technology.ivf_icsi.techniques,常规IVF; 单精子卵细胞浆内注射(ICSI); 睾丸/附睾精子提取,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,prevention.primary_prevention,避免生殖毒性物质接触; 健康生活方式; 适当运动; 控制体重; 戒烟限酒,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,prevention.secondary_prevention,及时治疗生殖道感染; 定期健康检查; 职业防护,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,prognosis.natural_conception,轻度异常患者可能自然受孕,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,prognosis.treatment_outcomes,激素治疗：60-80%改善; 手术治疗：成功率因病因而异; ART技术：成功率20-60%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,prognosis.factors_affecting_prognosis,病因类型; 女方年龄; 病程长短; 治疗依从性,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,name_en,Prostate Endocrine-Related Disorders,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,description,前列腺疾病中与内分泌激素调节相关的病理状态,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,icd_10,N40-N42,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.name,良性前列腺增生症,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.name_en,Benign Prostatic Hyperplasia (BPH),American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.description,前列腺细胞增殖导致腺体体积增大的良性疾病,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.epidemiology.prevalence,50岁以上男性约50%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.epidemiology.age_correlation,发病率随年龄增长而增加,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.epidemiology.geographic_variation,西方国家发病率较高,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.pathophysiology.hormonal_factors.dht_role,二氢睾酮(DHT)是主要刺激因子,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.pathophysiology.hormonal_factors.5alpha_reductase,5α-还原酶催化睾酮转化为DHT,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.pathophysiology.hormonal_factors.androgen_receptor,DHT与雄激素受体结合促进增生,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.pathophysiology.growth_factors,表皮生长因子(EGF); 成纤维细胞生长因子(FGF); 胰岛素样生长因子-1(IGF-1),American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.pathophysiology.estrogen_role,雌激素可能参与前列腺增生过程,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.clinical_manifestations.storage_symptoms,尿频; 尿急; 夜尿; 急迫性尿失禁,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.clinical_manifestations.voiding_symptoms,尿线细弱; 排尿困难; 尿流中断; 排尿后滴沥,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.clinical_manifestations.post_micturition_symptoms,残余尿感; 排尿后滴沥,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.diagnosis.clinical_assessment,国际前列腺症状评分(IPSS); 生活质量评分; 排尿日记,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.diagnosis.physical_examination,直肠指检评估前列腺大小,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.diagnosis.laboratory_tests,尿常规; 血清PSA; 肌酐（评估肾功能）,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.diagnosis.imaging,经腹部超声（残余尿测定）; 经直肠超声（前列腺体积）,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.benign_prostatic_hyperplasia.diagnosis.urodynamics,复杂病例或手术前评估,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.mechanism,阻断睾酮转化为DHT,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.medications.finasteride.dose,5mg/day,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.medications.finasteride.efficacy,可缩小前列腺体积20-30%,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.medications.finasteride.onset,3-6个月起效,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.medications.dutasteride.dose,0.5mg/day,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.medications.dutasteride.advantages,同时抑制两种5α-还原酶亚型,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.medications.dutasteride.efficacy,效果可能优于finasteride,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.side_effects,性欲减退; 勃起功能障碍; 射精异常; 乳房发育,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.5alpha_reductase_inhibitors.considerations,PSA水平降低约50%; 停药后症状可能复发; 可能降低前列腺癌风险,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.alpha_blockers.mechanism,松弛前列腺和膀胱颈平滑肌,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.alpha_blockers.medications,坦索罗辛 0.2-0.4mg/day; 阿夫唑嗪 2.5-10mg/day; 多沙唑嗪 1-8mg/day; 特拉唑嗪 1-10mg/day,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.alpha_blockers.onset,数天至数周,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.alpha_blockers.side_effects,体位性低血压; 头晕; 逆行射精; 鼻塞,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.combination_therapy.rationale,α受体阻滞剂+5α-还原酶抑制剂,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.combination_therapy.benefits,症状改善更显著; 降低疾病进展风险; 减少急性尿潴留发生,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,components.hormonal_therapy.combination_therapy.indications,中重度症状且前列腺体积>40ml,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,hormonal_considerations.testosterone_therapy_cautions,可能加重BPH症状; 需要密切监测前列腺; 定期PSA检测; 直肠指检,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,hormonal_considerations.age_related_changes,睾酮水平下降; 雌激素/雄激素比值改变; 前列腺对激素敏感性变化,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,treatment_monitoring.symptom_assessment,定期IPSS评分,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,treatment_monitoring.objective_measures,最大尿流率; 残余尿量; 前列腺体积,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,treatment_monitoring.safety_monitoring,PSA水平; 肾功能; 血压（α受体阻滞剂）,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,prognosis.natural_history,症状可能进行性加重,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,prognosis.treatment_response,症状改善：60-80%患者; 前列腺缩小：5α-还原酶抑制剂; 尿流改善：α受体阻滞剂,American Urological Association Male Hypogonadism Guidelines 2024
male_endocrine_entities,MAL_004,前列腺内分泌相关疾病,,prostate_endocrine_disorder,male_endocrine_disease,prognosis.long_term_outcomes,可能需要长期药物治疗; 部分患者最终需要手术; 生活质量通常显著改善,American Urological Association Male Hypogonadism Guidelines 2024
